Astal Laboratories Limited has completed its quarterly regulatory compliance by submitting the required certificate under SEBI (Depositories and Participants) Regulation 2018 for the quarter ended March 31, 2026. The pharmaceutical company, formerly known as Macro International Limited, filed the mandatory documentation with BSE Limited on April 9, 2026.

Regulatory Compliance Details

The submission pertains to Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018, which mandates quarterly reporting by registrar and share transfer agents. The certificate was prepared and issued by BEETAL Financial & Computer Services (P) Ltd, the company's appointed registrar and share transfer agent.

Certificate Confirmation

BEETAL Financial & Computer Services confirmed that all securities received from depository participants for dematerialization during the quarter ended March 2026 were properly processed and confirmed to the depositories. The registrar verified that:

• Securities received for dematerialization were confirmed (accepted/rejected) to depositories
• Securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within 15 days

Company Information

Astal Laboratories Limited operates with its registered office in Noida, Uttar Pradesh, and corporate office in Gachibowli, Telangana. The company secretary and compliance officer Mahendra Kumar digitally signed the submission document, ensuring proper authorization and compliance with regulatory requirements.

SEBI Regulatory Framework

The certificate submission aligns with SEBI circulars including NSDL/CIR/II/5/2019 dated January 25, 2019, CDSL/OPS/RTA/POLCY/2019/14 dated January 25, 2019, and SEBI letter ref no.MRD/DOP2/DSA2/OW/2019/2498/1 dated January 24, 2019. These guidelines ensure proper handling of dematerialized securities and maintain transparency in depositories operations.

Astral Laboratories Limited has disclosed a share acquisition by its promoter entity ACESO Research Labs LLP under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction represents a strategic increase in the promoter's stake in the pharmaceutical company.

Transaction Details

ACESO Research Labs LLP executed the share purchase through open market transactions on the BSE platform. The acquisition involved 21,007 equity shares, increasing the promoter's shareholding in the company.

Shareholding Changes

The acquisition resulted in an increase in ACESO Research Labs LLP's shareholding in Astral Laboratories Limited. The promoter's stake grew from 4.64% to 4.69% following the transaction.

Company Capital Structure

The disclosure reveals Astral Laboratories Limited's current capital structure, with the paid-up capital remaining unchanged post-transaction.

Regulatory Compliance

Astral Laboratories Limited submitted the disclosure to BSE Limited on March 19, 2026, through its Company Secretary and Compliance Officer, Mahendra Kumar. The disclosure was made under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically Regulation 29(2).

About the Entities

ACESO Research Labs LLP operates from Bangalore, Karnataka, and is represented by Designated Partner Ravikanti Shailaja (DIN: 07629653). Astral Laboratories Limited, formerly known as Macro International Limited, is incorporated under CIN L74120UP1993PLC015605 with its registered office in Noida, Uttar Pradesh, and corporate office in Hyderabad, Telangana. The company trades on BSE under scrip code 512600 with security ID ASTALLTD.